000 01589 a2200433 4500
005 20250515085049.0
264 0 _c20071019
008 200710s 0 0 eng d
022 _a0009-9236
024 7 _a10.1038/sj.clpt.6100348
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKravitz, R L
245 0 0 _aDirect-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.
_h[electronic resource]
260 _bClinical pharmacology and therapeutics
_cOct 2007
300 _a360-2 p.
_bdigital
500 _aPublication Type: Comment; Journal Article
650 0 4 _aConsumer Product Safety
650 0 4 _aDrug Industry
_xeconomics
650 0 4 _aDrug Information Services
_xeconomics
650 0 4 _aDrug Prescriptions
650 0 4 _aDrug Therapy
_xeconomics
650 0 4 _aDrug and Narcotic Control
650 0 4 _aDrug-Related Side Effects and Adverse Reactions
650 0 4 _aHealth Knowledge, Attitudes, Practice
650 0 4 _aHealth Promotion
650 0 4 _aHumans
650 0 4 _aMarketing of Health Services
_xeconomics
650 0 4 _aMass Media
650 0 4 _aModels, Econometric
650 0 4 _aPatient Education as Topic
650 0 4 _aPersuasive Communication
650 0 4 _aPhysician's Role
650 0 4 _aPractice Patterns, Physicians'
650 0 4 _aProduct Surveillance, Postmarketing
650 0 4 _aRisk Assessment
700 1 _aBell, R A
773 0 _tClinical pharmacology and therapeutics
_gvol. 82
_gno. 4
_gp. 360-2
856 4 0 _uhttps://doi.org/10.1038/sj.clpt.6100348
_zAvailable from publisher's website
999 _c17379162
_d17379162